title: Medical management of chronic liver diseases in children (part I): focus on curable or potentially curable diseases.
abstract: The management of children with chronic liver disease (CLD) mandates a multidisciplinary approach. CLDs can be classified into 'potentially' curable, treatable non-curable, and end-stage diseases. Goals pertaining to the management of CLDs can be divided into prevention or minimization of progressive liver damage in curable CLD by treating the primary cause; prevention or control of complications in treatable CLD; and prediction of the outcome in end-stage CLD in order to deliver definitive therapy by surgical procedures, including liver transplantation. Curative, specific therapies aimed at the primary causes of CLDs are, if possible, best considered by a pediatric hepatologist. Medical management of CLDs in children will be reviewed in two parts, with part I (this article) specifically focusing on 'potentially' curable CLDs. Dietary modification is the cornerstone of management for galactosemia, hereditary fructose intolerance, and certain glycogen storage diseases, as well as non-alcoholic steatohepatitis. It is also essential in tyrosinemia, in addition to nitisinone [2-(nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione] therapy, as well as in Wilson disease along with copper-chelating agents such as D-penicillamine, triethylenetetramine dihydrochloride, and ammonium tetrathiomolybdate. Zinc and antioxidants are adjuvant drugs in Wilson disease. New advances in chronic viral hepatitis have been made with the advent of oral antivirals. In children, currently available drugs for the treatment of chronic hepatitis B virus infection are standard interferon (IFN)-α-2, pegylated IFN-α-2 (PG-IFN), and lamivudine. In adults, adefovir and entecavir have also been licensed, whereas telbivudine, emtricitabine, tenofovir disoproxil fumarate, clevudine, and thymosin α-1 are currently undergoing clinical testing. For chronic hepatitis C virus infection, the most accepted treatment is PG-IFN plus ribavirin. Corticosteroids, with or without azathioprine, remain the basic strategy for inducing remission in autoimmune hepatitis. Ciclosporin (cyclosporine) and other immune suppressants may be used for patients who do not achieve remission, or who have significant side effects, with corticosteroid/azathioprine therapy. The above therapies can prevent, or at least minimize, progression of liver damage, particularly if started early, leading to an almost normal quality of life in affected children.
authors: Faculty of Medicine, Cairo University, Mohandesseen, Cairo, Egypt. melshabrawi@medicine.cu.edu.eg
authors: Mortada H F
authors: MH
authors: El-Shabrawi
authors: Naglaa M
authors: NM
authors: Kamal
mesh_terms: D002239:Carbohydrate Metabolism, Inborn Errors / Q000175:diagnosis / Q000178:diet therapy* / Q000188:drug therapy*; D002648:Child; D002662:Child Health Services / Q000379:methods*; D002908:Chronic Disease; D006521:Hepatitis, Chronic / Q000175:diagnosis / Q000178:diet therapy* / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D006527:Hepatolenticular Degeneration / Q000175:diagnosis / Q000178:diet therapy* / Q000188:drug therapy*; D006801:Humans; D011788:Quality of Life; D016896:Treatment Outcome